Osteopontin in Vascular Disease Friend or Foe?

被引:159
作者
Lok, Zoe Shin Yee [2 ]
Lyle, Alicia N. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA USA
[2] Monash Hlth, Sch Clin Sci, Dept Surg, Clayton, Vic, Australia
基金
美国国家卫生研究院;
关键词
atherosclerosis; cytokines; inflammation; osteopontin; risk factors; vascular diseases; SMOOTH-MUSCLE-CELLS; POTENTIAL CLINICAL-APPLICATIONS; PLASMA OSTEOPONTIN; CROSS-LINKING; ACCELERATED ATHEROSCLEROSIS; CIRCULATING OSTEOPONTIN; CARDIOVASCULAR-DISEASE; TERMINAL FRAGMENT; DIABETES-MELLITUS; DEFICIENT MICE;
D O I
10.1161/ATVBAHA.118.311577
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammatory cytokines are necessary for an acute response to injury and the progressive healing process. However, when this acute response does not resolve and becomes chronic, the same proteins that once promoted healing then contribute to chronic inflammatory pathologies, such as atherosclerosis. OPN (Osteopontin) is a secreted matricellular cytokine that signals through integrin and CD44 receptors, is highly upregulated in acute and chronic inflammatory settings, and has been implicated in physiological and pathophysiologic processes. Evidence from the literature suggests that OPN may fit within the Goldilocks paradigm with respect to cardiovascular disease, where acute increases are protective, attenuate vascular calcification, and promote postischemic neovascularization. In contrast, chronic increases in OPN are clinically associated with an increased risk for a major adverse cardiovascular event, and OPN expression is a strong predictor of cardiovascular disease independent of traditional risk factors. With the recent finding that humans express multiple OPN isoforms as the result of alternative splicing and that these isoforms have distinct biologic functions, future studies are required to determine what OPN isoform(s) are expressed in the setting of vascular disease and what role each of these isoforms plays in vascular disease progression. This review aims to discuss our current understanding of the role(s) of OPN in vascular disease pathologies using evidence from in vitro, animal, and clinical studies. Where possible, we discuss what is known about OPN isoform expression and our understanding of OPN isoform contributions to cardiovascular disease pathologies.
引用
收藏
页码:613 / 622
页数:10
相关论文
共 120 条
[1]   Plasma Osteopontin as a Predictor of Coronary Artery Disease: Association With Echocardiographic Characteristics of Atherosclerosis [J].
Abdel-Azeez, Hala Abdel-Hameed ;
Al-Zaky, Manar .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2010, 24 (03) :201-206
[2]   Angiotensin II-Induced osteopontin expression in vascular smooth muscle cells involves Gq/11, Ras, ERK, Src and Ets-1 [J].
Abe, Keiko ;
Nakashima, Hidekatsu ;
Ishida, Mari ;
Miho, Narimasa ;
Sawano, Mariko ;
Soe, Nwe Nwe ;
Kurabayashi, Masahiko ;
Chayama, Kazuaki ;
Yoshizumi, Masao ;
Ishida, Takafumi .
HYPERTENSION RESEARCH, 2008, 31 (05) :987-998
[3]   Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis [J].
Agah, Elmira ;
Zardoui, Arshia ;
Saghazadeh, Amene ;
Ahmadi, Mona ;
Tafakhori, Abbas ;
Rezaei, Nima .
PLOS ONE, 2018, 13 (01)
[4]   Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin) [J].
Agnihotri, R ;
Crawford, HC ;
Haro, H ;
Matrisian, LM ;
Havrda, MC ;
Liaw, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (30) :28261-28267
[5]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[6]   Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus [J].
Barchetta, I ;
Ceccarelli, V ;
Cimini, F. A. ;
Bertoccini, L. ;
Fraioli, A. ;
Alessandri, C. ;
Lenzi, A. ;
Baroni, M. G. ;
Cavallo, M. G. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (05) :513-520
[7]   Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile [J].
Barchetta, I. ;
Alessandri, C. ;
Bertoccini, L. ;
Cimini, F. A. ;
Taverniti, L. ;
Di Franco, M. ;
Fraioli, A. ;
Baroni, M. G. ;
Cavallo, M. G. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (02) :187-192
[8]   Identification of dual α4β1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin [J].
Bayless, KJ ;
Davis, GE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :13483-13489
[9]   Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease [J].
Berezin, A. E. ;
Kremzer, A. A. .
ATHEROSCLEROSIS, 2013, 229 (02) :475-481
[10]   High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention [J].
Bjerre, Mette ;
Pedersen, Sune H. ;
Mogelvang, Rasmus ;
Lindberg, Soren ;
Jensen, Jan S. ;
Galatius, Soren ;
Flyvbjerg, Allan .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2013, 20 (06) :922-929